Floatz logo

GTI 2040

Stage IIIC Colon Cancer

National Cancer Institute (NCI)nucleic_acidPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Stage IIIC Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sun Yat-sen University
Phase 3BBB
Eloxatin
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

GTI 2040 is also rated in:

cancer of unknown primary siteDormant
B
Indicative ·
63 / 100
View asset →
male breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →